Novel Technology for Therapeutic Oxygen Delivery


Respirogen micron-scale Oxygen Microbubble (OMB) technology will provide improved compositions and methods for blood oxygenation as well as improved methods for producing and delivering these oxygen delivery compositions to patients and explanted cells, tissues, or organs. Every cell in the body requires oxygen to maintain correct homeostasis, and hypoxic conditions can quickly lead to irreversible organ damage or death. OMB technology has demonstrated the ability to deliver oxygen to the blood stream independent of the lungs. 

Delivery of oxygen by O2 encapsulation within a micro-scale lipid microsphere


Tight control of the size and composition allows for microbubbles to carry oxygen, other gases, or therapeutic agents to targeted physiology: well characterized; easy to transport; stable; inexpensive to produce.

Targeted delivery will increase delivery effectiveness while reducing side effects compared to systemic infusions: oxygen can be retained within the microbubble until it encounters a hypoxic environment, facilitating targeted oxygen delivery to ischemic tissue and organs; lipid retention after delivery shows positive oncotic properties, increasing the blood volume and offering reduced morbidity in events of hemorrhage.

Delivery of oxygen by defined protocols: ability to deliver a quantified oxygen concentration over a defined time period to a specified anatomical region of interest; potential for a portable oxygen delivery therapy kit in first response or remote situations.



Peritoneal oxygenation - oxygen uptake without the lungs - has been validated in vivo in a small animal model

  • Rat model, pneumothorax injury [1]:  has shown 100% survival to 2 hours  (continuing, termination at 2 hrs) with peritoneal oxygenation by OMB vs control survival <30 minutes. 
  • Research continuing with Ben Terry PhD, U Nebraska, supported by 2018 USAF research grants



[1] J. A. Feshitan, N. D. Legband, M. A. Borden, and B. S. Terry, “Systemic oxygen delivery by peritoneal perfusion of oxygen microbubbles,” Biomaterials, vol. 35, no. 9, pp. 2600–2606, Mar. 2014.

[2] J. A. Feshitan, C. C. Chen, J. J. Kwan, and M. A. Borden, “Microbubble size isolation by differential centrifugation,” J. Colloid Interface Sci., vol. 329, no. 2, pp. 316–324, Jan. 2009.

[3] E. J. Swanson and M. A. Borden, “Injectable oxygen delivery based on protein-shelled microbubbles,” Nano LIFE, vol. 01, no. 03n04, pp. 215–218, Sep. 2010.